Last updated: 3 months ago
Renovaro Inc. Q3 2024 Financial Report: Losses Rise Amidst Biotechnology Opportunities
Explore Renovaro Inc.'s Q3 2024 financial report detailing a net loss of $44.21M, cash challenges, and growth potential in biotechnology and AI-driven healthcare.